ProCE Banner Activity

DESTINY-Breast03: Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Previously Treated HER2+ Metastatic Breast Cancer

Slideset Download
Conference Coverage
In a head-to-head trial in patients with previously treated HER2-positive metastatic breast cancer, trastuzumab deruxtecan reduced risk of disease progression or death by 72% compared with trastuzumab emtansine, a current standard of care.

Released: September 23, 2021

Expiration: September 22, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc